Analysis of Medicare Prescription Drug Plans In 2012 And Key Trends Since 2006
This report presents findings from an analysis of the Medicare Part D marketplace in 2012 and changes in drug coverage and costs since 2006.
View the Latest: Cost Sharing
Filter
-
-
Paying a Visit to the Doctor: Current Financial Protections for Medicare Patients When Receiving Physician Services
Issue BriefThis issue brief explains provisions in current law that shield beneficiaries from unexpected and confusing charges when they see physicians and practitioners—namely, the participating provider program, limitation on balance billing, and conditions on private contracting for doctors who opt out of Medicare or join “concierge” practices. It also analyzes the implications of modifying these provisions for beneficiaries, providers, and the Medicare program.
-
JAMA Forum: What Is Health Care Cost Containment?
Perspective"What Is Health Care Cost Containment?" Larry Levitt's September 2012 contribution to The JAMA Forum, is now available online.
-
How Much Skin in the Game is Enough? The Financial Burden of Health Spending for People on Medicare
ReportHow Much " Skin in the Game " is Enough? The Financial Burden of Health Spending for People on Medicare Medicare extends health security and financial protection to seniors and younger people with disabilities.
-
As Senate Weighs Bipartisan Stabilization Bill with Cost-Sharing Reduction Funding, Current Marketplace Enrollees Face Challenges with Affordability
News ReleaseKnowledge and Awareness of Key Facts Regarding Enrollment Is Low As the Nov. 1 start of the Affordable Care Act’s open enrollment period nears, new polling data from the Kaiser Family Foundation finds that most potential enrollees are unaware of when they can enroll and have not seen any related advertisements.
-
Most private insurers are no longer waiving cost-sharing for COVID-19 treatment
Issue BriefThis analysis finds nearly three quarters of the largest health plans in each state are no longer waiving enrollees’ cost-sharing requirements for COVID-19 treatment as of August 2021. Insurers largely waived those costs early in the pandemic, before safe and effetive vaccines were available.
-
How Might the FDA’s Approval of a New Alzheimer’s Drug Impact Medicaid?
Issue BriefThe brief examines the potential impact of Aduhelm, a newly approved drug for Alzheimer's disease, on state and federal Medicaid costs and looks at potential policy actions that could limit Medicaid’s potential costs.
-
Data Note: Public Worries About And Experience With Surprise Medical Bills
FeatureThis data note captures February 2020 poll findings on the public's worries about and experiences with unexpected and surprise medical bills.
-
Web Briefing for Media: 2018 Employer Health Benefits Survey
Event Date:EventThe Kaiser Family Foundation held a reporters-only web briefing on Oct. 3, 2018, to release the 2018 benchmark Employer Health Benefits Survey. This 20th annual survey provides a detailed look at the current state of employer-based coverage and trends in private health insurance for both large and small firms.
-
What Happens When COVID-19 Emergency Declarations End? Implications for Coverage, Costs, and Access
Issue BriefThis brief provides an overview of the major health-related COVID-19 federal emergency declarations that have been made since early on in the pandemic, summarizes the flexibilities triggered by each, and identifies the implications for their ending, related to coverage, costs, and payment for COVID-19 testing, treatments, and vaccines; Medicaid coverage and federal match rates; telehealth; access to medical countermeasures through FDA emergency use authorization (EUA); and other Medicaid, Medicare and private health insurance flexibilities.